Role of Epigenetics for the Efficacy of Cisplatin
The clinical utility of the chemotherapeutic agent cisplatin is restricted by cancer drug resistance, which is either intrinsic to the tumor or acquired during therapy. Epigenetics is increasingly recognized as a factor contributing to cisplatin resistance and hence influences drug efficacy and clin...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/2/1130 |
| _version_ | 1797339758703149056 |
|---|---|
| author | Tatjana Lumpp Sandra Stößer Franziska Fischer Andrea Hartwig Beate Köberle |
| author_facet | Tatjana Lumpp Sandra Stößer Franziska Fischer Andrea Hartwig Beate Köberle |
| author_sort | Tatjana Lumpp |
| collection | DOAJ |
| description | The clinical utility of the chemotherapeutic agent cisplatin is restricted by cancer drug resistance, which is either intrinsic to the tumor or acquired during therapy. Epigenetics is increasingly recognized as a factor contributing to cisplatin resistance and hence influences drug efficacy and clinical outcomes. In particular, epigenetics regulates gene expression without changing the DNA sequence. Common types of epigenetic modifications linked to chemoresistance are DNA methylation, histone modification, and non-coding RNAs. This review provides an overview of the current findings of various epigenetic modifications related to cisplatin efficacy in cell lines in vitro and in clinical tumor samples. Furthermore, it discusses whether epigenetic alterations might be used as predictors of the platinum agent response in order to prevent avoidable side effects in patients with resistant malignancies. In addition, epigenetic targeting therapies are described as a possible strategy to render cancer cells more susceptible to platinum drugs. |
| first_indexed | 2024-03-08T09:53:02Z |
| format | Article |
| id | doaj.art-9103574578d44c6ba55064e5b234def2 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-08T09:53:02Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9103574578d44c6ba55064e5b234def22024-01-29T13:57:18ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-01-01252113010.3390/ijms25021130Role of Epigenetics for the Efficacy of CisplatinTatjana Lumpp0Sandra Stößer1Franziska Fischer2Andrea Hartwig3Beate Köberle4Department Food Chemistry and Toxicology, Institute of Applied Biosciences, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, GermanyDepartment Food Chemistry and Toxicology, Institute of Applied Biosciences, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, GermanyDepartment Food Chemistry and Toxicology, Institute of Applied Biosciences, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, GermanyDepartment Food Chemistry and Toxicology, Institute of Applied Biosciences, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, GermanyDepartment Food Chemistry and Toxicology, Institute of Applied Biosciences, Karlsruhe Institute of Technology, Adenauerring 20a, 76131 Karlsruhe, GermanyThe clinical utility of the chemotherapeutic agent cisplatin is restricted by cancer drug resistance, which is either intrinsic to the tumor or acquired during therapy. Epigenetics is increasingly recognized as a factor contributing to cisplatin resistance and hence influences drug efficacy and clinical outcomes. In particular, epigenetics regulates gene expression without changing the DNA sequence. Common types of epigenetic modifications linked to chemoresistance are DNA methylation, histone modification, and non-coding RNAs. This review provides an overview of the current findings of various epigenetic modifications related to cisplatin efficacy in cell lines in vitro and in clinical tumor samples. Furthermore, it discusses whether epigenetic alterations might be used as predictors of the platinum agent response in order to prevent avoidable side effects in patients with resistant malignancies. In addition, epigenetic targeting therapies are described as a possible strategy to render cancer cells more susceptible to platinum drugs.https://www.mdpi.com/1422-0067/25/2/1130epigeneticspromoter methylationhistone modificationmiRNAlncRNAcisplatin resistance |
| spellingShingle | Tatjana Lumpp Sandra Stößer Franziska Fischer Andrea Hartwig Beate Köberle Role of Epigenetics for the Efficacy of Cisplatin International Journal of Molecular Sciences epigenetics promoter methylation histone modification miRNA lncRNA cisplatin resistance |
| title | Role of Epigenetics for the Efficacy of Cisplatin |
| title_full | Role of Epigenetics for the Efficacy of Cisplatin |
| title_fullStr | Role of Epigenetics for the Efficacy of Cisplatin |
| title_full_unstemmed | Role of Epigenetics for the Efficacy of Cisplatin |
| title_short | Role of Epigenetics for the Efficacy of Cisplatin |
| title_sort | role of epigenetics for the efficacy of cisplatin |
| topic | epigenetics promoter methylation histone modification miRNA lncRNA cisplatin resistance |
| url | https://www.mdpi.com/1422-0067/25/2/1130 |
| work_keys_str_mv | AT tatjanalumpp roleofepigeneticsfortheefficacyofcisplatin AT sandrastoßer roleofepigeneticsfortheefficacyofcisplatin AT franziskafischer roleofepigeneticsfortheefficacyofcisplatin AT andreahartwig roleofepigeneticsfortheefficacyofcisplatin AT beatekoberle roleofepigeneticsfortheefficacyofcisplatin |